Charles Schwab
SGP

Charles Schwab’s SpyGlass Pharma SGP Stock Holding History

Charles Schwab’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
85,681
+26,071
+44% +$566K ﹤0.01% 2806
2026
Q1 		$1.54M Buy
+59,610
New +$1.6M ﹤0.01% 2778

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's SGP Position: Q2 2026 in Review

Charles Schwab increased its SpyGlass Pharma (SGP) stake by 44% in Q2 2026, buying an estimated $566K and bringing the position to 85,681 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Charles Schwab first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Charles Schwab held 85,681 shares of SpyGlass Pharma worth $1.91M as of Q2 2026.
  • Charles Schwab bought 26,071 SpyGlass Pharma shares in Q2 2026, an estimated $566K.
  • SpyGlass Pharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2806 holding.
  • Charles Schwab first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.